LYFE Sciences · Project HERA
Variant Interpretation · Classification Report
Generated: 2026-11-19
Case ID: NM_004119.2_c.1664T_A_20261119_134234
Framework: ACMG/AMP 2015 with custom FLT3 criterion specifications
Variant classification summary

NM_004119.2:c.1664T>A

FLT3  · NP_004110.2:p.(Ile555Asn)  · NM_004119.2
GRCh37: chr13:28608478 A>T  ·  GRCh38: chr13:28034341 A>T
Gene: FLT3 Transcript: NM_004119.2
Final call
VUS
PM2 moderate
All criteria require review: For research and educational purposes only.
Gene
FLT3
Transcript
NM_004119.2
Protein
NP_004110.2:p.(Ile555Asn)
gnomAD AF
1.2390591080756917e-06 (v4.1)
ClinVar
OncoKB
Unknown Oncogenic Effect
Interpretation summary
Generated evidence synthesis
1
PM2 Moderate: gnomAD v4.1 frequency is 1.23906e-06 with zero homozygotes.
2
VUS: PM2 Moderate alone satisfies no pathogenic or benign combination rule.
Final determination: Under the local FLT3 framework's ACMG/AMP combination rules, one Moderate criterion alone does not meet any Pathogenic, Likely Pathogenic, Benign, or Likely Benign rule; therefore the call is VUS.
ACMG/AMP criteria review
Criteria shown when status is available
All criteria require review: For research and educational purposes only.
Criterion Status Rationale Evidence used
PVS1 N/A Not applicable: c.1664T>A is a missense substitution, not one of the null-variant classes required for PVS1.
pvs1_variant_assessment
PS1 Not met Not met: no previously established pathogenic variant producing FLT3 p.Ile555Asn was identified for this missense substitution.
PS2 Not assessed Not assessed: no proband-level de novo evidence or confirmed maternity and paternity testing is available for p.Ile555Asn.
PS3 Not assessed Not assessed: no variant-specific functional assay was identified, and OncoKB reports Unknown Oncogenic Effect rather than exact-variant functional evidence.
oncokb PMID:40637740 vcep_flt3_itd_hotspot_and_function vcep_flt3_oncokb_guidance
PS4 Not met Not met: no variant-specific affected-versus-control carrier counts, odds ratio, or confidence interval were reported for p.Ile555Asn.
PMID:40637740
PM1 Not met Not met: FLT3 residue 555 is outside the governing codons 589-599 hotspot, and vcep_materials.json lists no approved critical-domain entry for residue 555.
vcep_flt3_itd_hotspot_and_function hotspots
PM2 Met Met at Moderate: gnomAD v4.1 total AF is 1.23906e-06 with 0 homozygotes, below the <=0.0001 PM2 cutoff.
gnomad_v2 gnomad_v4
PM3 N/A Not applicable: PM3 is restricted to recessive disorders, but no recessive FLT3 disorder or in-trans pathogenic allele is established.
PM4 N/A Not applicable: p.Ile555Asn changes one amino acid but causes no protein-length change required for PM4.
pvs1_variant_assessment vcep_flt3_itd_hotspot_and_function
PM5 Not met Not met: no different pathogenic missense variant at FLT3 residue 555 was identified, and the local PM5 note excludes this missense SNV.
vcep_flt3_itd_hotspot_and_function vcep_flt3_oncokb_guidance pm5_candidates
PM6 Not assessed Not assessed: no assumed de novo occurrence or parental testing data are reported for p.Ile555Asn.
PP1 Not assessed Not assessed: zero affected relatives and zero informative co-segregating meioses are documented for p.Ile555Asn.
PP2 Not assessed Not assessed: the required FLT3 benign-missense rate and evidence that missense variants commonly cause disease are not provided.
PP3 Not met Not met: missense REVEL score 0.561 is below the PP3 supporting threshold of >= 0.644.
revel
PP4 Not assessed Not assessed: no patient phenotype, family history, or disease diagnosis is available to evaluate phenotype specificity.
PP5 Not met Not met: the exact variant has no ClinVar expert-panel pathogenic or likely pathogenic classification.
BA1 Not met Not met: gnomAD v4.1 grpmax FAF is 3.65e-06 (0.000365%), far below the >=0.05 BA1 threshold.
gnomad_v4
BS1 Not met Not met: gnomAD v4.1 grpmax FAF is 3.65e-06 (0.000365%), below the generic 0.01 BS1 threshold.
gnomad_v4
BS2 Not assessed Not assessed: gnomAD has 0 homozygotes, but disease model, penetrance, and healthy-adult status for the rare heterozygotes are unavailable.
gnomad_v2 gnomad_v4
BS3 Not assessed Not assessed: no variant-specific assay demonstrated a lack of damaging effect on FLT3 protein function or splicing.
oncokb PMID:40637740 vcep_flt3_itd_hotspot_and_function vcep_flt3_oncokb_guidance
BS4 Not assessed Not assessed: no affected relatives have documented negative testing, so no non-segregation event is available for BS4.
BP1 Not assessed Not assessed: no validated evidence shows that FLT3 disease is caused primarily by truncating variants.
BP2 Not assessed Not assessed: no reported pathogenic partner variant or parental phase result establishes cis or trans occurrence for p.Ile555Asn.
BP3 N/A Not applicable: p.Ile555Asn is a missense SNV, not an in-frame deletion or insertion in a repetitive region.
pvs1_variant_assessment vcep_flt3_itd_hotspot_and_function
BP4 Not met Not met: missense REVEL score 0.561 is above the BP4 supporting threshold of <= 0.29.
revel
BP5 Not assessed Not assessed: no case-level alternate molecular basis for disease is documented alongside this variant.
BP6 Not met Not met: the exact variant has no ClinVar expert-panel benign or likely benign classification.
BP7 N/A Not applicable: c.1664T>A is missense with p.(Ile555Asn), not a synonymous variant.
Disclaimer: The content and results provided by LYFE Sciences are for research and educational purposes only and must not be used as a substitute for professional medical judgment, diagnosis, or treatment. Always consult a qualified healthcare professional before making any clinical decisions.